Table 3.
Associations of metabolic factors and chronic disease with plasma 8-OHdG and F2-isoprostanes.
| 8-OHdGa | F2-isoprostanesb | |||
|---|---|---|---|---|
| β | p | β | p | |
| Waist circumference (cm) | −0.06 | 0.071 | 0.08 | 0.026 |
| Triglyceridesc (mmol/L) | −0.04 | 0.231 | 0.21 | <0.001 |
| HDL-cholesterolc (mmol/L) | −0.01 | 0.831 | 0.23 | <0.001 |
| LDL-cholesterolc (mmol/L) | −0.05 | 0.176 | 0.19 | <0.001 |
| Fasting glucosec (mmol/L) | −0.01 | 0.742 | 0.02 | 0.573 |
| Systolic blood pressurec (mm Hg) | −0.02 | 0.482 | 0.13 | <0.001 |
| Diastolic blood pressurec (mm Hg) | −0.04 | 0.215 | 0.13 | <0.001 |
|
| ||||
| Metabolic syndrome (Mets) (Yes (ref. No)) | −0.05 | 0.143 | 0.08 | 0.013 |
| N of MetS components | −0.04 | 0.198 | 0.11 | 0.001 |
|
| ||||
| N of chronic diseases | 0.01 | 0.713 | 0.00 | 0.988 |
8-OHdG and F2-isoprostanes were logged transformed for analysis. All analyses were adjusted for research site. Results are reported as standardized regression coefficients. aAnalyses on 8-OHdG were adjusted for age, sex, cotinine, and fasting. bAnalyses on F2-isoprostanes were adjusted for age, sex, education, cotinine, alcohol use, supplement use, season of sample collection, and fasting.
cTriglycerides, HDL-cholesterol, LDL-cholesterol, fasting glucose, systolic and diastolic blood pressure were all adjusted for use of lipid, cholesterol, and glucose or blood pressure lowering medication. HDL: high-density lipoprotein; LDL: low-density lipoprotein; N: number; MetS: metabolic syndrome.